X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement allows Statera the right to supply the IgY products for the existing approved markets. Statera also receives the right to license and commercialize current and future products for other indications.
Lead Product(s): Avian Antibody
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Lay Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 13, 2022
Details:
Statera will receive milestones, new indications and royalties, Crohn’s disease and COVID-19 indications and regulatory approvals, payments from Immune Therapeutics in exchange for Statera’s rights to any product containing low-dose naltrexone as an active ingredient.
Lead Product(s): Naltrexone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: STAT-205
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Immune Therapeutics
Deal Size: $402.0 million Upfront Cash: $2.0 million
Deal Type: Agreement April 27, 2022
Details:
Under the terms of the definitive agreement, Statera will receive upfront payment and revenue-based milestone payments from Coeptis in exchange for Statera’s rights to any product containing Entolimod as an active ingredient and all other related TLR5 agonists.
Lead Product(s): Entolimod
Therapeutic Area: Oncology Product Name: CBLB502
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coeptis Therapeutics
Deal Size: Undisclosed Upfront Cash: $6.0 million
Deal Type: Agreement April 13, 2022
Details:
STAT-205 may show promise in treating both acute COVID infections and long COVID in this manner. Preliminary in vitro data demonstrated the drug’s ability to slow or halt the progression of SARS-CoV-2 (the virus that causes COVID-19) in human lung cells.
Lead Product(s): Naltrexone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: STAT-205
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
This financing will be used for general corporate purposes, including the Company’s Phase 3 pediatric Crohn’s study for STAT-201, its acute COVID study, as well as other development activities.
Lead Product(s): STAT-201
Therapeutic Area: Gastroenterology Product Name: STAT-201
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EF Hutton
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 09, 2022
Details:
STAT-201, Statera’s most advanced drug candidate, in Phase 2 study demonstrated proof of concept and safety as well as remission in 67% of participants and 43% of true mucosal healing with endoscopies.
Lead Product(s): STAT-201
Therapeutic Area: Gastroenterology Product Name: STAT-201
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2021
Details:
Statera is establishing a development program in Oncology and Hematology based on the potential that toll-like receptor 5 agonists, such as Entolimod, have shown in the treatment of neutropenia and anemia in cancer patients.
Lead Product(s): Entolimod
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: STAT-600
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2021
Details:
During preclinical in vitro studies, STAT-205 demonstrated an ability to inhibit the replication of coronaviruses in human lung cells. Data also shows that STAT-205 could prevent life-threatening lung inflammation caused by COVID-19, as well as lessen the risk of reinfection.
Lead Product(s): STAT-205
Therapeutic Area: Infections and Infectious Diseases Product Name: STAT-205
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
